Almost 20 years later, the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi) olaparib became the first synthetic lethality-based treatment approved by the Food and Drug Administration (FDA) as a single-agent therapy for BRCA-deficient ovarian and breast cancer patients [6]. Here, PARP1 is linked to breast cancer.